The Medicines Co boosts hospital presence with Incline purchase, Recothrom deal
This article was originally published in Scrip
Executive Summary
The Medicines Company will make an initial investment of $300 million to expand its hospital presence with the $185 million purchase of Incline Therapeutics and its Ionsys system for the short-term management of acute post-operative pain, as well as $115 million in collaboration and option fees for a two-year exclusive global license to market the topical hemostat Recothrom from Bristol-Myers Squibb.